380 related articles for article (PubMed ID: 22161318)
1. Cardiovascular toxicity of anticancer-targeted therapy: emerging issues in the era of cardio-oncology.
Raschi E; De Ponti F
Intern Emerg Med; 2012 Apr; 7(2):113-31. PubMed ID: 22161318
[TBL] [Abstract][Full Text] [Related]
2. Bringing new players into the field: onco-pharmacovigilance in the era of cardio-oncology.
Albini A; Donatelli F; Noonan D; D'Elios MM; Prisco D
Intern Emerg Med; 2012 Apr; 7(2):99-101. PubMed ID: 22271393
[No Abstract] [Full Text] [Related]
3. Cardio-oncology: conflicting priorities of anticancer treatment and cardiovascular outcome.
Tilemann LM; Heckmann MB; Katus HA; Lehmann LH; Müller OJ
Clin Res Cardiol; 2018 Apr; 107(4):271-280. PubMed ID: 29453595
[TBL] [Abstract][Full Text] [Related]
4. Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention.
Albini A; Pennesi G; Donatelli F; Cammarota R; De Flora S; Noonan DM
J Natl Cancer Inst; 2010 Jan; 102(1):14-25. PubMed ID: 20007921
[TBL] [Abstract][Full Text] [Related]
5. Emergence of cardio-oncology.
Nebigil CG; Désaubry L
Ann Pharm Fr; 2018 Nov; 76(6):504-506. PubMed ID: 30075937
[TBL] [Abstract][Full Text] [Related]
6. Future Directions in Cardio-Oncology.
Trachtenberg BH
Methodist Debakey Cardiovasc J; 2019; 15(4):300-302. PubMed ID: 31988691
[No Abstract] [Full Text] [Related]
7. The Burgeoning Field of Cardio-Oncology.
Trachtenberg BH
Methodist Debakey Cardiovasc J; 2019; 15(4):241-242. PubMed ID: 31988683
[No Abstract] [Full Text] [Related]
8. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
9. Cardiac toxicity from systemic cancer therapy: a comprehensive review.
Curigliano G; Mayer EL; Burstein HJ; Winer EP; Goldhirsch A
Prog Cardiovasc Dis; 2010; 53(2):94-104. PubMed ID: 20728696
[TBL] [Abstract][Full Text] [Related]
10. Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell.
Sayed N; Ameen M; Wu JC
Cardiovasc Res; 2019 Apr; 115(5):949-959. PubMed ID: 30768178
[TBL] [Abstract][Full Text] [Related]
11. From cardio-oncology to cardio-onco-pharmacology: Towards a multidisciplinary approach in the understanding and management of cardiotoxicity.
Ederhy S; Devos P; Cohen A; Pinna B; Bretagne M; Nguyen LS; Salem JE
Therapie; 2022; 77(2):197-206. PubMed ID: 34895759
[TBL] [Abstract][Full Text] [Related]
12. An update on cardio-oncology.
Herrmann J; Lerman A
Trends Cardiovasc Med; 2014 Oct; 24(7):285-95. PubMed ID: 25153017
[TBL] [Abstract][Full Text] [Related]
13. Practices in management of cancer treatment-related cardiovascular toxicity: A cardio-oncology survey.
Jovenaux L; Cautela J; Resseguier N; Pibarot M; Taouqi M; Orabona M; Pinto J; Peyrol M; Barraud J; Laine M; Bonello L; Paganelli F; Barlesi F; Thuny F
Int J Cardiol; 2017 Aug; 241():387-392. PubMed ID: 28365180
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxic effects of chemotherapy: A review of both cytotoxic and molecular targeted oncology therapies and their effect on the cardiovascular system.
Babiker HM; McBride A; Newton M; Boehmer LM; Drucker AG; Gowan M; Cassagnol M; Camenisch TD; Anwer F; Hollands JM
Crit Rev Oncol Hematol; 2018 Jun; 126():186-200. PubMed ID: 29759560
[TBL] [Abstract][Full Text] [Related]
15. What Does a Cardio-oncology Service Offer to the Oncologist and the Haematologist?
Andres MS; Pan J; Lyon AR
Clin Oncol (R Coll Radiol); 2021 Aug; 33(8):483-493. PubMed ID: 33832839
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological foundations of cardio-oncology.
Minotti G; Salvatorelli E; Menna P
J Pharmacol Exp Ther; 2010 Jul; 334(1):2-8. PubMed ID: 20335321
[TBL] [Abstract][Full Text] [Related]
17. Cardio-oncological management of patients.
Cardinale DM; Barac A; Torbicki A; Khandheria BK; Lenihan D; Minotti G
Semin Oncol; 2019 Dec; 46(6):408-413. PubMed ID: 31784042
[TBL] [Abstract][Full Text] [Related]
18. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
[TBL] [Abstract][Full Text] [Related]
19. Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.
Lyon AR; Dent S; Stanway S; Earl H; Brezden-Masley C; Cohen-Solal A; Tocchetti CG; Moslehi JJ; Groarke JD; Bergler-Klein J; Khoo V; Tan LL; Anker MS; von Haehling S; Maack C; Pudil R; Barac A; Thavendiranathan P; Ky B; Neilan TG; Belenkov Y; Rosen SD; Iakobishvili Z; Sverdlov AL; Hajjar LA; Macedo AVS; Manisty C; Ciardiello F; Farmakis D; de Boer RA; Skouri H; Suter TM; Cardinale D; Witteles RM; Fradley MG; Herrmann J; Cornell RF; Wechelaker A; Mauro MJ; Milojkovic D; de Lavallade H; Ruschitzka F; Coats AJS; Seferovic PM; Chioncel O; Thum T; Bauersachs J; Andres MS; Wright DJ; López-Fernández T; Plummer C; Lenihan D
Eur J Heart Fail; 2020 Nov; 22(11):1945-1960. PubMed ID: 32463967
[TBL] [Abstract][Full Text] [Related]
20. Timely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist.
Bonura F; Di Lisi D; Novo S; D'Alessandro N
Cardiovasc Toxicol; 2012 Jun; 12(2):93-107. PubMed ID: 21894547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]